- Home
- GNPX vs BOLT Comparison
GNPX vs BOLT Comparison
Compare GNPX & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- BOLT
- Stock Information
- Founded
- GNPX 2009
- BOLT 2015
- Country
- GNPX United States
- BOLT United States
- Employees
- GNPX N/A
- BOLT N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- BOLT Health Care
- Exchange
- GNPX Nasdaq
- BOLT Nasdaq
- Market Cap
- GNPX 9.4M
- BOLT 10.4M
- IPO Year
- GNPX 2018
- BOLT 2021
- Fundamental
- Price
- GNPX $0.24
- BOLT $6.41
- Analyst Decision
- GNPX
- BOLT Buy
- Analyst Count
- GNPX 0
- BOLT 3
- Target Price
- GNPX N/A
- BOLT $47.50
- AVG Volume (30 Days)
- GNPX 3.8M
- BOLT 36.2K
- Earning Date
- GNPX 11-12-2025
- BOLT 11-11-2025
- Dividend Yield
- GNPX N/A
- BOLT N/A
- EPS Growth
- GNPX N/A
- BOLT N/A
- EPS
- GNPX N/A
- BOLT N/A
- Revenue
- GNPX N/A
- BOLT $4,167,000.00
- Revenue This Year
- GNPX N/A
- BOLT N/A
- Revenue Next Year
- GNPX N/A
- BOLT N/A
- P/E Ratio
- GNPX N/A
- BOLT N/A
- Revenue Growth
- GNPX N/A
- BOLT N/A
- 52 Week Low
- GNPX $0.14
- BOLT $4.59
- 52 Week High
- GNPX $3.97
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- GNPX 48.99
- BOLT 60.64
- Support Level
- GNPX $0.19
- BOLT $5.13
- Resistance Level
- GNPX $0.22
- BOLT $6.25
- Average True Range (ATR)
- GNPX 0.02
- BOLT 0.33
- MACD
- GNPX -0.00
- BOLT 0.09
- Stochastic Oscillator
- GNPX 49.82
- BOLT 80.17
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.